An observational study in Acute Myocardial Infarction, sponsored by CellProthera. Recruiting at 10 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-25.
Sponsored by CellProthera · Observational
Among 168 studies in Myocardial Infarction with a site in France — 22 open to participants now, 31 under way, 7 of them phase 3. Myocardial Infarction · France.
Among the 168 studies in Myocardial Infarction with a site in France, this one is the 49th largest by planned enrollment of the 54 observational ones that give a count, is one of 9 that started in 2024, is one of 54 observational ones, reaches primary completion later than 29 of the 30 other live ones, and was the 157th registered.
2,270 studies on the registry are indexed under Myocardial Infarction; 371 are open to participants now.
Browse Myocardial Infarction studies →22 of the 168 studies in Myocardial Infarction with a site in France are open now. Recruiting first, the newest first:
University Hospital, Clermont-Ferrand · Sites in France
Ages 18–80
French Cardiology Society · Sites in France
Ages 18–60 · Women only
Centre Hospitalier Universitaire, Amiens · Sites in France
Ages 18+
University Hospital, Angers · Sites in France
Ages 18+
Fondation Hôpital Saint-Joseph · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 255 Myocardial Infarction studies recruiting now, 172 (67%) set no upper age limit and 26 (10%) stop at 75 or younger; 16 take children under 18; 27 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
168 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 14 · Phase 3 42 · Phase 4 14
First in 2002; this study’s year is marked. 9 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 48 is below the median of 568 across 814 observational studies indexed under Myocardial Infarction.
Median enrollment 332 across the 114 interventional studies, 756 across the 54 observational. Of the 124 that completed or were terminated, 24 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 168 have an industry lead sponsor. The 10 most frequent:
CellProthera is the lead sponsor of 4 studies on the registry; 1 is open to participants now.
CellProthera has 3 studies filed under Myocardial Infarction — fewer than ten, so there is no comparison to draw.
8 of the studies in Myocardial Infarction with a site in France that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06118281Phase 3Novo Nordisk A/SARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack | 2027-01-29 |
| NCT05577988Phase 3Assistance Publique - Hôpitaux de ParisAssessment of an Early De-Escalation to a Low-potency Single Antiplatelet Therapy Guided by Genetics Versus a Systematic High-Potency Single Antiplatelet Therapy to Neutralize Bleeding Complications in Patients With High Bleeding Risk Beyond One Month After an Acute Coronary Syndrome | 2027-06 |
| NCT04957719Phase 3Viatris Innovation GmbHSelatogrel Outcome Study in Suspected Acute Myocardial Infarction | 2027-07 |
| NCT05476991Phase 3Assistance Publique - Hôpitaux de ParisEvaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis | 2027-09-01 |
| NCT02762162Action, FranceRegistry of Coronary Artery Ill Patients With Platelet Test Results | 2027-01 |
Add all 8 to your calendar (.ics) → With an account.
Among the 168 studies in Myocardial Infarction with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The PERFECT study is an observational study designed to follow patients randomised in the EXCELLENT study (NCT02669810) for 10 years.
The aim is to assess the long-term clinical outcomes for patients randomised to the Standard of Care arm or the ProtheraCytes arm.
To be eligible for this observational study, participants must have completed the last visit in the EXCELLENT interventional clinical trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria :
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients randomized in the standard of care arm in the EXCELLENT trial who have completed their 6-month follow-up visit
Other: NA - Observational study
Patients randomized in the ProtheraCytes arm in the EXCELLENT trial, who received an injection of ProtheraCytes and who have completed their 6-month follow-up visit
Other: NA - Observational study
Observational study, data collection only.
Comparison of the safety and efficacy of patients included in the Protheracytes arm versus the Standard of care arm
The data collected for the efficacity part are cardiovascular markers : NT-Pro-BNP, LVESVI, LVEDVI, LVEF The data collected for the safety are : Occurence of Acute Heart failure, Acute MI, transplantation or MACE. All SAE/AE ongoing at or starting from the participant's last visit of the EXCELLENT clinical trial until 10 years after enrolment
Time frame: Through study completion, an average of 10 year
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Started Jul 2024 (actual). Primary completion is estimated for Mar 2034, 115 months after the start.
Of 37 industry-sponsored observational studies under Myocardial Infarction, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 32. This study's planned 115 months is above that.
Counting every sponsor, half of 333 studies reached it within 48 months; a quarter within 17 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
CellProthera